We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimized Radiological Diagnosis of Hepatic Candidiasis During the Treatment of Acute Leukemias

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01207843
Recruitment Status : Completed
First Posted : September 23, 2010
Last Update Posted : August 19, 2014
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

Hepatic candidiasis is a frequent complication in patients receiving intensive chemotherapy for acute leukemia. Hepatic lesions may be detected by computerized tomographic (CT) scans, but there is no standardized CT protocol for the diagnosis and follow-up of hepatic candidiasis.

The investigators compared the size of the fungal lesions in the chest and abdomen CT. The current analysis aimed to increase the value of CT for the diagnosis and the follow-up of hepatic candidiasis in daily routine.


Condition or disease Intervention/treatment Phase
Leukemia Infection Behavioral: Imaging Phase 4

Study Design

Study Type : Observational
Actual Enrollment : 88 participants
Time Perspective: Retrospective
Official Title: Verbesserung Der Radiologischen Diagnose Von Hepatolienaler Candidiasis während Der Therapie Der Leukämie
Study Start Date : October 2009
Primary Completion Date : April 2011
Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Intervention Details:
    Behavioral: Imaging
    CT image validation and lesion measurement, as well as comparison of different CT phases

Outcome Measures

Primary Outcome Measures :
  1. The primary end-point was IFI according to the EORTC/MSG 2008 definitions and bacteraemia [ Time Frame: 2 Years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients with suspected hepatolienal candidiasis.
Criteria

Inclusion criteria:

  • Chest and Abdomen CT with fungal lesion in patients with leukemia

Exclusion criteria:

  • Other liver pathologies
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01207843


Locations
Switzerland
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Thomas Frauenfelder, MD UniversitaetsSpital Zuerich
More Information

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01207843     History of Changes
Other Study ID Numbers: idr-3d-001
First Posted: September 23, 2010    Key Record Dates
Last Update Posted: August 19, 2014
Last Verified: August 2014

Keywords provided by University of Zurich:
Computed tomography

Additional relevant MeSH terms:
Leukemia
Candidiasis
Neoplasms by Histologic Type
Neoplasms
Mycoses